What are the common side effects of bedaquiline? how to cope

Bedaquiline (Bedaquiline) is a targeted drug that has been widely used in the treatment of drug-resistant tuberculosis in recent years. Although it has shown significant advantages in anti-tuberculosis efficacy, its safety still requires close attention. The most common adverse reactions include electrocardiogramQT interval prolongation, abnormal liver function, nausea, joint pain, headache and fatigue. Among them, prolongation of the QT interval is considered to be the most important potential risk of bedaquiline. If other drugs that may also prolong the QT interval, such as moxifloxacin or clofazimine, are used in combination, the electrocardiogram needs to be monitored regularly to prevent serious adverse cardiac events such as arrhythmia.

The metabolism of bedaquiline mainly depends on the liverCYP3A4 enzyme system, so its use may lead to abnormal liver function such as elevated transaminases, especially when combined with other hepatotoxic drugs such as prothionamide or ethambutol. Liver enzyme indicators such as ALT and AST should be closely monitored. Once a significant increase is found, the dose should be reduced or discontinued in time, and alternative drugs should be used if necessary. In addition, some patients will experience mild discomfort such as nausea, fatigue, and muscle soreness in the early stages of medication. Most of these are transient reactions, which can be effectively relieved through a reasonable diet, appropriate rest, and symptomatic treatment, and no forced discontinuation of medication is required.

The key to dealing with bedaquiline-related side effects lies in dynamic monitoring before, during and after treatment and early identification of risk factors. An electrocardiogram and baseline liver function assessment are required before treatment, especially for patients with a history of heart disease or chronic liver disease who need to carefully assess the risks of medication. During treatment, the QT interval should be monitored at least once a month. At the same time, attention should be paid to whether other QT prolonging drugs are used concomitantly, and the combination regimen should be adjusted if necessary. During long-term medication, the dose should be adjusted appropriately based on the patient's response. If serious adverse reactions occur, the medication should be discontinued promptly and alternative treatment strategies should be sought.

Reference materials:https://en.wikipedia.org/wiki/Bedaquiline